Prostate-specific membrane antigen (PSMA) is a cell-surface protein that is highly expressed in prostate cancer [1] and also in the endothelium of the tumour neovasculature of several solid tumours [2], including glioblastoma (GBM) [3,4,5,6], making it an excellent target for antibody–drug conjugates or peptide receptor radionuclide therapy [3]. Here, FOLH1 is linked to prostate cancer.